249 related articles for article (PubMed ID: 24602025)
1. Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
Picard M; Pham Dang N; D'Incan M; Mansard S; Dechelotte P; Pereira B; Mondie JM; Barthelemy I
Br J Dermatol; 2014 Jul; 171(1):108-14. PubMed ID: 24602025
[TBL] [Abstract][Full Text] [Related]
2. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutation screening in melanoma: is sentinel lymph node reliable?
Nardin C; Puzenat E; Prétet JL; Algros MP; Doussot A; Puyraveau M; Mougin C; Aubin F
Melanoma Res; 2015 Aug; 25(4):328-34. PubMed ID: 26020488
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
7. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study.
Pasquali S; Mocellin S; Mozzillo N; Maurichi A; Quaglino P; Borgognoni L; Solari N; Piazzalunga D; Mascheroni L; Giudice G; Patuzzo R; Caracò C; Ribero S; Marone U; Santinami M; Rossi CR
J Clin Oncol; 2014 Mar; 32(9):935-41. PubMed ID: 24516022
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
[TBL] [Abstract][Full Text] [Related]
9. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
10. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
11. Analysis of predictive factors for the outcome of complete lymph node dissection in melanoma patients with metastatic sentinel lymph nodes.
Kunte C; Geimer T; Baumert J; Konz B; Volkenandt M; Flaig M; Ruzicka T; Berking C; Schmid-Wendtner MH
J Am Acad Dermatol; 2011 Apr; 64(4):655-62; quiz 637. PubMed ID: 21315477
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
13. Incidence and location of positive nonsentinel lymph nodes in head and neck melanoma.
Gyorki DE; Boyle JO; Ganly I; Morris L; Shaha AR; Singh B; Wong RJ; Shah JP; Busam K; Kraus D; Coit DG; Patel S
Eur J Surg Oncol; 2014 Mar; 40(3):305-10. PubMed ID: 24361245
[TBL] [Abstract][Full Text] [Related]
14. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
Zdzienicki M; Rutkowski P; Nowecki ZI; van Akkooi AC; Michej W; Dziewirski W; Świtaj T; Pieńkowski A; Sałamacha M; Bylina E; Eggermont AM
Eur J Surg Oncol; 2013 Mar; 39(3):304-10. PubMed ID: 23298828
[TBL] [Abstract][Full Text] [Related]
15. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
Keijzer R; Bril H; van der Loo EM; de Graaf PW
Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
[TBL] [Abstract][Full Text] [Related]
16. The role of BRAF mutations in primary melanoma growth rate and survival.
Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
[TBL] [Abstract][Full Text] [Related]
17. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
[TBL] [Abstract][Full Text] [Related]
19. [Prognosis after sentinel node biopsy in malignant melanoma].
Lock-Andersen J; Horn J; Sjøstrand H
Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutation-positive folliculotropic metastatic melanoma.
Brick KE; Halling KC; Khan YK; Peters MS
Am J Dermatopathol; 2013 Jul; 35(5):609-12. PubMed ID: 23715079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
